Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.58 |
| ▸ | AHCY | P23526 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590551 | 0.84 | ADORA2A (0.73) | ADORA2AADORA2BADORA1ADORA3TMIGD3 | |
| Trifluoroacetic Acid SCHEMBL1402076 | 0.80 | ADORA2A (0.57) | ADORA2AADORA2BADORA1ADORA3TMIGD3 | |
| SCHEMBL1402080 | 0.79 | ADORA2A (0.53) | ADORA2AADORA2BADORA1ADORA3TMIGD3 | |
| Trifluoroacetic Acid SCHEMBL589376 | 0.79 | ADORA2A (0.68) | ADORA2AADORA2BADORA1ADORA3TMIGD3 | |
| SCHEMBL448798 | 0.78 | AHCY (0.56) | ADORA2AADORA3AHCY | |
| SCHEMBL10587027 | 0.78 | ADORA2A (0.82) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL8373469 | 0.78 | ADORA2A (0.82) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5163682 | 0.75 | ADORA1 (0.75) | ADORA2AADORA2BADORA1ADORA3TMIGD3 | |
| SCHEMBL5161127 | 0.74 | ADORA2A (0.85) | ADORA2AADORA2BADORA1ADORA3TMIGD3 | |
| SCHEMBL7209277 | 0.74 | ADORA2A (0.80) | ADORA2AADORA2BADORA1ADORA3TMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2026-04-30 | — | — | US | disclosed |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | CAN-FITE BIOPHARMA LTD. (IL) | 2025-02-04 | — | — | US | disclosed |
| EP-3530273-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF A SEXUAL DYSFUNCTION | CAN FITE BIOPHARMA LTD (IL) | 2024-08-14 | — | — | EP | disclosed |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2022-04-05 | — | — | US | disclosed |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2022-03-17 | — | — | US | disclosed |
| CN-113543790-A | Use of A for achieving a fat-reducing effect3Adenosine receptor ligands | 坎-菲特生物药物有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-108367016-B | A3 adenosine receptor ligands for the treatment of ectopic fat accumulation | 坎-菲特生物药物有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-9549943-B2 | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | CAN-FITE BIOPHARMA LTD. (IL) | 2017-01-24 | — | — | US | disclosed |
| US-20150216889-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | CAN-FITE BIOPHARMA LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-8557790-B2 | A3 adenoside receptor agonists for the reduction of intraocular pressure | CAN-FITE BIOPHARMA LTD. (IL) | 2013-10-15 | — | — | US | disclosed |
| US-20120065155-A1 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | CAN-FITE BIOPHARMA LTD. (IL) | 2012-03-15 | — | — | US | disclosed |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-02 | — | — | US | disclosed |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | CAN-FITE BIOPHARMA LTD. (IL) | 2008-12-04 | — | — | US | disclosed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | disclosed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | disclosed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | GPR119, FABP1, INSR | ADORA2A 4/4885ADORA2B 7/4885ADORA1 18/4885 |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | ADORA2A, ADORA3, FABP4 | ADORA2A 1/4885ADORA2B 7/4885ADORA1 4/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 4/4885ADORA1 3/4885 |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA2B 3/4885ADORA1 4/4885 |
| US-20150216889-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA2B 3/4885ADORA1 4/4885 |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA2B, ADORA3, ADORA2A | ADORA2A 3/4885ADORA2B 1/4885ADORA1 4/4885 |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 4/4885ADORA1 3/4885 |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | ADORA3, ADORA2A, FABP4 | ADORA2A 2/4885ADORA2B 5/4885ADORA1 4/4885 |
| US-20120065155-A1 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | ADORA3, ADORA1, ADORA2A | ADORA2A 3/4885ADORA2B 4/4885ADORA1 2/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 5/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.